ArticleCancer cell international2019

NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma.

Yong Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.